CGEN-15091 is a soluble fusion protein composed of the extracellular domain of a newly discovered B7/CD28 like protein fused to a Fc antibody fragment. This novel B7/CD28 like protein was discovered by Compugen using its Protein Family Members Discovery Platform.

CGEN-15091 demonstrated pronounced therapeutic efficacy in experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (MS). In this model, short-term treatment with CGEN-15091 resulted in long-term alleviation in clinical manifestation of the disease. The effect on disease symptoms is accompanied by inhibition of ‘epitope spreading’ – a phenomenon that underlies the relapsing nature of the disease. In cell based assays CGEN-15091 was demonstrated to inhibit T cell activation. Altogether this data support the therapeutic potential of CGEN-15091 for treatment of autoimmune diseases.